A Phase 1 Open-label, Multicenter, Randomized, 2-period, Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

Trial Profile

A Phase 1 Open-label, Multicenter, Randomized, 2-period, Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 5 Feb 2018 to 5 Sep 2018.
    • 28 Jun 2017 Planned primary completion date changed from 18 Jan 2018 to 18 Aug 2018.
    • 19 May 2017 Planned number of patients changed from 60 to 90.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top